Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Lipum AB: BioStock: Lipum's CEO summarizes the half-year - continued positive study data

Lipum

Lipum's report for the first half of 2024 highlights the positive interim results from the phase I study with SOL-116. The company has started preparations for phase II trials in rheumatoid arthritis, including initiating the collaboration with NorthX Biologics for the manufacturing of SOL-116. BioStock reached out to Lipum's CEO Ola Sandborgh to learn more about these development, as well as the audit report of the Horizon 2020 project which may result in them being liable for repayment.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/08/lipums-ceo-summarizes-the-half-year-continued-positive-study-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team